StÃ©phane Depil

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/483886/publications.pdf

Version: 2024-02-01

93 papers	3,789 citations	172457 29 h-index	133252 59 g-index
102 all docs	102 docs citations	102 times ranked	6938 citing authors

#	Article	IF	Citations
1	Cold Tumors: A Therapeutic Challenge for Immunotherapy. Frontiers in Immunology, 2019, 10, 168.	4.8	733
2	â€˜Off-the-shelfâ€™ allogeneic CAR T cells: development and challenges. Nature Reviews Drug Discovery, 2020, 19, 185-199.	46.4	632
3	Decoding and unlocking the BCL-2 dependency of cancer cells. Nature Reviews Cancer, 2013, 13, 455-465.	28.4	194
4	Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer. Cancer Research, 2013, 73, 813-823.	0.9	182
5	Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Annals of Oncology, 2017, 28, 1756-1766.	1.2	123
6	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression. Clinical Cancer Research, 2013, 19, 6520-6531.	7.0	122
7	Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. Leukemia, 2002, 16, 254-259.	7.2	121
8	TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer. PLoS ONE, 2013, 8, e63712.	2.5	120
9	Granulocyteâ€“macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. Journal of Biological Chemistry, 2019, 294, 5430-5437.	3.4	114
10	Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends in Biotechnology, 2012, 30, 575-582.	9.3	94
11	Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnology, 2019, 19, 44.	3.3	87
12	Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers. Cancer Cell, 2016, 29, 173-185.	16.8	80
13	S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab. Molecular Cancer Therapeutics, 2013, 12, 1749-1762.	4.1	78
14	Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. British Journal of Cancer, 2016, 114, 177-187.	6.4	67
15	Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. Transplantation, 2004, 78, 1697-1701.	1.0	64
16	Cancer-Associated Fibroblasts Produce Netrin-1 to Control Cancer Cell Plasticity. Cancer Research, 2019, 79, 3651-3661.	0.9	62
17	A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. Leukemia, 2006, 20, 1557-1565.	7.2	52
18	Epsteinâ€“Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. British Journal of Haematology, 2014, 166, 875-890.	2.5	49

#	Article	IF	Citations
19	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. Science Translational Medicine, 2019, 11, .	12.4	49
20	Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplantation, 2004, 33, 531-534.	2.4	48
21	Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in Cancers. Cancers, 2020, 12, 610.	3.7	44
22	Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor TÂcell functionality. Nature Communications, 2019, 10, 5100.	12.8	42
23	Phase II study of gemcitabineâ€“dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Annals of Oncology, 2007, 18, 370-375.	1.2	38
24	Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts. PLoS ONE, 2014, 9, e80836.	2.5	38
25	Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Science Advances, 2022, 8, eabj3671.	10.3	38
26	Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer. Cell Death and Disease, 2014, 5, e1423-e1423.	6.3	36
27	Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts. PLoS ONE, 2014, 9, e91325.	2.5	34
28	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Investigational New Drugs, 2015, 33, 423-431.	2.6	33
29	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death and Disease, 2013, 4, e738-e738.	6.3	30
30	Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. European Journal of Cancer, 2013, 49, 2791-2797.	2.8	29
31	Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies. Journal of Immunotherapy, 2007, 30, 215-226.	2.4	24
32	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152.	1.8	22
33	SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia, 2003, 17, 1678-1679.	7.2	20
34	Neoepitopes-based vaccines: challenges and perspectives. European Journal of Cancer, 2019, 108, 55-60.	2.8	20
35	Toward â€œoffâ€theâ€shelfâ€•allogeneic CAR T cells. Advances in Cell and Gene Therapy, 2020, 3, e86.	0.9	20
36	Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection. Vaccine, 2007, 25, 5927-5937.	3.8	19

#	Article	IF	Citations
37	HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. Breast Cancer Research and Treatment, 2015, 149, 81-89.	2.5	19
38	TIPIN depletion leads to apoptosis in breast cancer cells. Molecular Oncology, 2015, 9, 1580-1598.	4.6	19
39	EBV Latency II-derived Peptides Induce A Specific CD4+ Cytotoxic T-cell Activity and Not A CD4+ Regulatory T-cell Response. Journal of Immunotherapy, 2012, 35, 254-266.	2.4	18
40	Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. Oncotarget, 2017, 8, 56210-56227.	1.8	17
41	Comparative analysis of naÃ¯ve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSFâ€“mobilized peripheral blood stem cell allografts: impact of donor characteristics. Experimental Hematology, 2007, 35, 861-871.	0.4	16
42	A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. Annals of Oncology, 2019, 30, v159.	1.2	13
43	Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma. Leukemia and Lymphoma, 2004, 45, 2481-2484.	1.3	11
44	Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. Leukemia Research, 2005, 29, 665-671.	0.8	11
45	Peptide-binding assays and HLA II transgenic AÎ²Â° mice are consistent and complementary tools for identifying HLA II-restricted peptides. Vaccine, 2006, 24, 2225-2229.	3.8	11
46	Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma. Gene, 2016, 580, 134-143.	2.2	9
47	A case of refractory anemia with 17pâ^' syndrome following azathioprine treatment for heart transplantation. Leukemia, 2004, 18, 878-878.	7.2	8
48	Efficient generation of antileukemic autologous T cells by short-term culture and ?-irradiation of myeloid leukemic cells. Cancer Immunology, Immunotherapy, 2004, 53, 793-8.	4.2	8
49	Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454,) Tj ETQq1 1 0.784314 rgBT /Overlock	3.5	8
50	<scp>HERVs</scp> characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. American Journal of Hematology, 2022, 97, 1200-1214.	4.1	8
51	Primary Central Nervous System Lymphoma in Immunocompetent Adults: Poor Results Mainly Associated with High Treatment Related Toxicities. Leukemia and Lymphoma, 2002, 43, 1819-1822.	1.3	7
52	Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. British Journal of Haematology, 2005, 129, 706-707.	2.5	6
53	Abstract 3000: Molecular profiling of residual tumor cells after various chemotherapies shows distinct gene expression patterns in patient-derived breast cancer xenografts. Cancer Research, 2012, 72, 3000-3000.	0.9	5
54	Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients. Leukemia and Lymphoma, 2005, 46, 841-849.	1.3	4

#	Article	IF	Citations
55	Abstract 5130: Integrative approaches for the identification of therapeutic targets in basal like breast cancer from multi-level molecular data. , 2012, , .		4
56	Abstract 2921: Preclinical characteristics of NP137, a first-in-class monoclonal antibody directed against netrin-1 and inducing dependence receptors-mediated cell death. , 2015, , .		3
57	Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy. European Journal of Cancer, 2022, 171, 96-105.	2.8	3
58	Cancer vaccines: whatâ€™s next?. Oncotarget, 2019, 10, 3985-3987.	1.8	2
59	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients. Blood, 2012, 120, 3643-3643.	1.4	2
60	Chemotherapy increases transgene expression in leukemic cells. Journal of Gene Medicine, 2003, 5, 852-859.	2.8	1
61	Abstract 4373: LRP5: a potential therapeutic target in triple-negative breast cancer.. , 2013, , .		1
62	Abstract 2764: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target. , 2014, , .		1
63	576 Integrative Approaches for the Identification of Therapeutic Targets in Basal-like Breast Cancer From Multi-level Molecular Data. European Journal of Cancer, 2012, 48, S137.	2.8	0
64	777 Antitumor Activity of the New Bcl-2/Bcl-xl Inhibitor S44563 in Primary Human Uveal Melanoma Xenografts. European Journal of Cancer, 2012, 48, S185.	2.8	0
65	829 Polo-like Kinase 1 â€“ a Potential Therapeutic Target for the Management of Patients With Triple Negative Breast Cancer. European Journal of Cancer, 2012, 48, S199.	2.8	0
66	947 Molecular Profiling of Residual Tumor Cells After Various Chemotherapies Shows Distinct Gene Expression Patterns in Patient-derived Breast Cancer Xenografts. European Journal of Cancer, 2012, 48, S228.	2.8	0
67	524 LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer. European Journal of Cancer, 2012, 48, 161-162.	2.8	0
68	63 IN VIVO RADIOSENSITIZER EFFECT OF THE HDAC INHIBITOR S78454 ON ORTHOTOPIC HUMAN GLIOBLASTOMA. Radiotherapy and Oncology, 2012, 102, S22.	0.6	0
69	368 NP137, the first humanized monoclonal antibody directed against netrin-1, exhibits antitumor activity by inducing dependence receptors-mediated cell death. European Journal of Cancer, 2014, 50, 118-119.	2.8	0
70	CHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists. Annals of Oncology, 2018, 29, x9.	1.2	0
71	Abstract B85: In vivo radiosensitizer effect of the HDAC inhibitor S78454 on orthotopic human glioblastoma.. , 2011, , .		0
72	Abstract A57: Targeting breast cancer stem cells by inducing cell differentiation using histone deacetylase inhibitor S78454.. , 2011, , .		0

#	Article	IF	Citations
73	Abstract A240: Preclinical molecular stratification of human tumors sensitive or resistant to S 49076, a novel MET/FGFR/AXL kinase inhibitor.. , 2011, , .		0
74	Abstract A238: S 49076, a novel, potent, MET/FGFR/AXL kinase inhibitor with wide antitumor activity.. , 2011, , .		0
75	Abstract A192: PK/PD modeling-based optimization of administration schedule for the histone deacetylase inhibitor (HDACi) S78454/PCI-24781 in phase I.. , 2011, , .		0
76	Abstract A107: S 78454/PCI-24781, a novel HDAC inhibitor, targets the DNA damage response leading to radiosensitization of both normoxic and hypoxic NSCLC cell lines.. , 2011, , .		0
77	Abstract B217: Antitumor activity of the new Bcl-2/Bcl-xl inhibitor S44563 in primary human uveal melanoma xenografts.. , 2011, , .		0
78	Abstract 848: Preclinical antitumor activity of S 49076, a novel MET / AXL / FGFR kinase inhibitor and molecular stratification for tumor sensitivity. , 2012, , .		0
79	Abstract 2782: Bcl-2 selective antagonists show antitumor activity without dose limiting platelet toxicity. , 2012, , .		0
80	Abstract 4702: Antitumor activity of a novel histone deacetylase inhibitor S78454 in EBV-associated nasopharyngeal carcinoma. , 2012, , .		0
81	Abstract 2022: P53-dependent thrombocytopenia induced by the histone deacetylase inhibitor S78454. , 2012, , .		0
82	Abstract 4704: Effects of the HDAC inhibitor S78454/PCI-24781 on ER signalling in ERÎ±-positive antiestrogen-sensitive and -resistant breast cancer cells. , 2012, , .		0
83	Abstract 4891: Radiation enhances the efficacy of Bcl-2 and Bcl-XLinhibition in small cell lung cancer: A new concept of using radiation for targeted therapy through contextual oncogene addiction. , 2012, , .		0
84	Abstract 2938: Polo-like kinase 1: a potential therapeutic target for the management of patients with triple negative breast cancer. , 2012, , .		0
85	Antitumor evaluation of the new Bcl-2/Bcl-xl inhibitor S44563 in primary human uveal melanoma xenografts. Acta Ophthalmologica, 2012, 90, 0-0.	1.1	0
86	Abstract 1013: Treatment of EBV-positive nasopharyngeal carcinoma xenografts with the HDAC-inhibitor Abexinostat: synergy with cis-platinum.. , 2013, , .		0
87	Abstract C219: Novel MET/FGFR/AXL kinase inhibitor S49076 exerts radiosensitizing activity in vitro and in vivo.. , 2013, , .		0
88	Abstract C65: First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.. , 2013, , .		0
89	Abstract B233: The depletion of LRP5, unlike that of LRP6, promotes apoptosis in triple-negative breast cancer cells, making it an interesting therapeutic target.. , 2013, , .		0
90	Abstract OT1-4-05: Phase I dose-escalation study of oral administration of abexinostat (S 78454,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 .		0

#	Article	IF	Citations
91	Abstract 4934: Immunostimulatory and oncolytic properties of rotavirus can overcome resistance to immune checkpoint blockade therapy. , 2018, , .		0
92	Abstract LB-078: Effect of a combined immune checkpoint inhibitor and mechanical focused ultrasound treatment on intratumoral immune response in a MC38 preclinical model. , 2020, , .		0
93	691â€…Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy. , 2021, 9, A719-A719.		0